MX2024006747A - Metodos y regimenes de dosificacion que comprenden un inhibidor de cinasa 2 dependiente de ciclina (cdk2) y un inhibidor de cinasa 4 dependiente de ciclina (cdk4) para el tratamiento de cancer. - Google Patents

Metodos y regimenes de dosificacion que comprenden un inhibidor de cinasa 2 dependiente de ciclina (cdk2) y un inhibidor de cinasa 4 dependiente de ciclina (cdk4) para el tratamiento de cancer.

Info

Publication number
MX2024006747A
MX2024006747A MX2024006747A MX2024006747A MX2024006747A MX 2024006747 A MX2024006747 A MX 2024006747A MX 2024006747 A MX2024006747 A MX 2024006747A MX 2024006747 A MX2024006747 A MX 2024006747A MX 2024006747 A MX2024006747 A MX 2024006747A
Authority
MX
Mexico
Prior art keywords
inhibitor
methods
treating cancer
dosing regimens
cdk2
Prior art date
Application number
MX2024006747A
Other languages
English (en)
Spanish (es)
Inventor
Jing Yang
Tun Tun Lin
Lars Anders
Jerry Li
Todd Lee Vanarsdale
Ping Wei
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2024006747A publication Critical patent/MX2024006747A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2024006747A 2021-12-02 2022-12-01 Metodos y regimenes de dosificacion que comprenden un inhibidor de cinasa 2 dependiente de ciclina (cdk2) y un inhibidor de cinasa 4 dependiente de ciclina (cdk4) para el tratamiento de cancer. MX2024006747A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163285457P 2021-12-02 2021-12-02
PCT/IB2022/061652 WO2023100134A1 (en) 2021-12-02 2022-12-01 Methods and dosing regimens comprising a cdk2 inhibitor and a cdk4 inhibitor for treating cancer

Publications (1)

Publication Number Publication Date
MX2024006747A true MX2024006747A (es) 2024-06-19

Family

ID=84462534

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024006747A MX2024006747A (es) 2021-12-02 2022-12-01 Metodos y regimenes de dosificacion que comprenden un inhibidor de cinasa 2 dependiente de ciclina (cdk2) y un inhibidor de cinasa 4 dependiente de ciclina (cdk4) para el tratamiento de cancer.

Country Status (12)

Country Link
US (1) US20250041277A1 (cg-RX-API-DMAC10.html)
EP (1) EP4440575A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024544625A (cg-RX-API-DMAC10.html)
KR (1) KR20240112932A (cg-RX-API-DMAC10.html)
CN (1) CN118647379A (cg-RX-API-DMAC10.html)
AU (2) AU2022402512A1 (cg-RX-API-DMAC10.html)
CA (1) CA3241001A1 (cg-RX-API-DMAC10.html)
IL (1) IL312980A (cg-RX-API-DMAC10.html)
MX (1) MX2024006747A (cg-RX-API-DMAC10.html)
TW (1) TWI873485B (cg-RX-API-DMAC10.html)
WO (1) WO2023100134A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA202404615B (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3217792A1 (en) 2021-05-07 2022-11-10 Kymera Therapeutics, Inc Cdk2 degraders and uses thereof
EP4604961A1 (en) * 2022-10-18 2025-08-27 Pfizer Inc. Compounds for the treatment of cancer
EP4719405A1 (en) * 2023-06-02 2026-04-08 Pfizer Inc. Methods and modified dosing regimens comprising a cdk4 inhibitor for the treatment of cancer
WO2025202871A1 (en) * 2024-03-27 2025-10-02 Pfizer Inc. Methods for identifying biomarkers of treatment response and use thereof with a cdk4 inhibitor
WO2025202854A1 (en) * 2024-03-27 2025-10-02 Pfizer Inc. Cdk4 inhibitors and combinations with cdk2 inhibitors or further agents for use in the treatment of cancer
WO2026024674A1 (en) 2024-07-22 2026-01-29 Genesis Therapeutics, Inc. Methods of treating skp2-associated cancers
WO2026133192A1 (en) * 2024-12-20 2026-06-25 Pfizer Inc. Combination therapies using cdk4 inhibitors with pd-1 axis binding antagonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
CN118286225A (zh) 2018-04-26 2024-07-05 辉瑞公司 作为细胞周期蛋白依赖性激酶抑制剂的2-氨基-吡啶或2-氨基-嘧啶衍生物
CA3128155C (en) 2019-01-31 2023-09-19 Pfizer Inc. 3-carbonylamino-5-cyclopentyl-1h-pyrazole compounds having inhibitory activity on cdk2

Also Published As

Publication number Publication date
AU2026201311A1 (en) 2026-03-12
IL312980A (en) 2024-07-01
US20250041277A1 (en) 2025-02-06
KR20240112932A (ko) 2024-07-19
TW202332431A (zh) 2023-08-16
ZA202404615B (en) 2025-12-17
TWI873485B (zh) 2025-02-21
WO2023100134A1 (en) 2023-06-08
CA3241001A1 (en) 2023-06-08
CN118647379A (zh) 2024-09-13
EP4440575A1 (en) 2024-10-09
AU2022402512A1 (en) 2024-06-20
JP2024544625A (ja) 2024-12-03

Similar Documents

Publication Publication Date Title
ZA202404615B (en) Methods and dosing regimens comprising a cdk2 inhibitor and a cdk4 inhibitor for treating cancer
CR20170014A (es) Métodos para tratar el cáncer con inhibidores de tigit y agentes contra el cáncer
BR112017022845A2 (pt) neoepítopos de câncer
AR102553A1 (es) Terapia de combinación con agonistas de unión ox40 e inhibidores de tigit
MX2023001527A (es) Compuestos con actividad inductora de ferroptosis y metodos de uso de estos.
CR20190252A (es) Compuestos de 7-feniletilamino-4h-pirimido[4,5-d][1,3]-oxazin-2-ona como inhibidores de idh1 e idh2 mutantes
MX2018014188A (es) Derivados de pirazol como inhibidores de calicreina plasmatica.
MX2019010149A (es) Inhibicion del smarca2 para el tratamiento del cancer.
BR112018072560A2 (pt) terapia de combinação para tratamento do câncer
BR112020009655A8 (pt) Anticorpo, usos de um anticorpo e uso de uma combinação farmacêutica
MX2016013027A (es) Uso de dianhidrogalactitol y analogos o derivados del mismo para tratar cancer de celulas no pequeñas del pulmon y cancer de ovario.
NI201900009A (es) MÉTODOS PARA TRATAR EL CÁNCER DE PRÓSTATA Se describen métodos para tratar el c
MX340724B (es) Terapia anti-angiogenesis para el tratamiento del cancer de mama.
BR112017017700A2 (pt) métodos, composições e kits para tratamento do câncer
MX2019011657A (es) Combinacion de un anticuerpo anti ligando 1 de muerte programada (pd-l1) e inhibidor de proteina cinasa dependiente de acido desoxirribonucleico (dna-pk) para tratamiento de cancer.
BR112015023203A2 (pt) métodos para tratamento de câncer, para aumentar a eficiência de um tratamento de câncer, para retardar e/ou prevenir o desenvolvimento de câncer, para tratar um indivíduo com câncer, para aumentar a sensibilidade para um agente de terapia para câncer, para estender um período de sensibilidade e para estender a duração da resposta para uma terapia para câncer, e usos
CO2022000481A2 (es) Inhibidores de enzimas
BR112017023517A2 (pt) anticorpo anti-cd20 para tratamento do câncer, composição farmacêutica, método de tratamento de um paciente que sofre de câncer e uso de um anticorpo anti-cd20
MX2023000549A (es) Combinaciones para el tratamiento de neoplasias usando localizacion de celulas quiescentes e inhibidores de egfr.
MX2019010040A (es) Composiciones y métodos para el tratamiento del cáncer.
BR112022012885A2 (pt) Método para tratar um câncer que expressa cd70 em um sujeito, composição farmacêutica para o tratamento de um câncer que expressa cd70, e, kit
BR112019002689A2 (pt) terapia com rapamicina tópica
ECSP20077106A (es) Régimen de dosificación para el tratamiento de trastornos relacionados con pi3k
MX2021003263A (es) Combinacion de un antagonista de proteina de muerte programada 1 (pd-1), un inhibidor de ataxia telangiectasia y proteina relacionada con rad3 (atr) y un agente de platino para el tratamiento de cancer.
MX2020006808A (es) Ubicar al complejo de signalosoma cbm induce a las celulas t reguladoras inflamar al microambiente tumoral.